Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
- PMID: 27095655
- DOI: 10.1038/nrgastro.2016.51
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
Abstract
Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies with features of biliary tract differentiation. CCA is the second most common primary liver tumour and the incidence is increasing worldwide. CCA has high mortality owing to its aggressiveness, late diagnosis and refractory nature. In May 2015, the "European Network for the Study of Cholangiocarcinoma" (ENS-CCA: www.enscca.org or www.cholangiocarcinoma.eu) was created to promote and boost international research collaboration on the study of CCA at basic, translational and clinical level. In this Consensus Statement, we aim to provide valuable information on classifications, pathological features, risk factors, cells of origin, genetic and epigenetic modifications and current therapies available for this cancer. Moreover, future directions on basic and clinical investigations and plans for the ENS-CCA are highlighted.
Similar articles
-
Targeting cholangiocarcinoma.Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1454-1460. doi: 10.1016/j.bbadis.2017.08.027. Epub 2017 Aug 24. Biochim Biophys Acta Mol Basis Dis. 2018. PMID: 28844952 Free PMC article. Review.
-
Epigenome Remodeling in Cholangiocarcinoma.Trends Cancer. 2019 Jun;5(6):335-350. doi: 10.1016/j.trecan.2019.05.002. Epub 2019 Jun 4. Trends Cancer. 2019. PMID: 31208696 Review.
-
Molecular classification of cholangiocarcinoma.Curr Opin Gastroenterol. 2020 Mar;36(2):57-62. doi: 10.1097/MOG.0000000000000611. Curr Opin Gastroenterol. 2020. PMID: 31895230 Review.
-
The ATO/miRNA-885-5p/MTPN axis induces reversal of drug-resistance in cholangiocarcinoma.Cell Oncol (Dordr). 2021 Aug;44(4):907-916. doi: 10.1007/s13402-021-00610-3. Epub 2021 Jun 25. Cell Oncol (Dordr). 2021. PMID: 34170484
-
The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma.Hepatology. 2021 Sep;74(3):1357-1370. doi: 10.1002/hep.31799. Epub 2021 Aug 26. Hepatology. 2021. PMID: 33709535
Cited by
-
Circulating miR-18a and miR-532 Levels in Extrahepatic Cholangiocarcinoma.J Clin Med. 2024 Oct 17;13(20):6177. doi: 10.3390/jcm13206177. J Clin Med. 2024. PMID: 39458127 Free PMC article.
-
Lymph node metastasis of intrahepatic cholangiocarcinoma: the present and prospect of detection and dissection.Eur J Gastroenterol Hepatol. 2024 Dec 1;36(12):1359-1369. doi: 10.1097/MEG.0000000000002856. Epub 2024 Oct 30. Eur J Gastroenterol Hepatol. 2024. PMID: 39475782 Free PMC article. Review.
-
Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma.Oncoimmunology. 2024 Oct 1;13(1):2406052. doi: 10.1080/2162402X.2024.2406052. eCollection 2024. Oncoimmunology. 2024. PMID: 39359389 Free PMC article.
-
Beyond ribosomal function: RPS6 deficiency suppresses cholangiocarcinoma cell growth by disrupting alternative splicing.Acta Pharm Sin B. 2024 Sep;14(9):3931-3948. doi: 10.1016/j.apsb.2024.06.028. Epub 2024 Jun 29. Acta Pharm Sin B. 2024. PMID: 39309509 Free PMC article.
-
Imaged periductal infiltration: Diagnostic and prognostic role in intrahepatic mass-forming cholangiocarcinoma.Eur J Radiol Open. 2024 Feb 16;12:100554. doi: 10.1016/j.ejro.2024.100554. eCollection 2024 Jun. Eur J Radiol Open. 2024. PMID: 38390438 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous